- Home
- CMPX
as 04-18-2025 1:33pm EST
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 229.5M | IPO Year: | N/A |
| Target Price: | $13.38 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $4.08 | Next Earning Date: | 05-12-2025 |
| Revenue: | $850,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 47.65% | Revenue Growth (next year): | 2767.57% |
Stock Insider Trading Activity of Compass Therapeutics Inc. (CMPX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GORDON CARL L | CMPX | Director10% Owner | Apr 9 '25 | Sell | $1.59 | 3,571,428 | $5,678,570.52 | 0 | |
| Anderman Jonathan | CMPX | Gen Counsel & Corporate Sec | Apr 7 '25 | Buy | $1.54 | 20,000 | $30,800.00 | 21,000 | |
| Lerner Neil | CMPX | CHIEF ACCOUNTING OFFICER | Apr 7 '25 | Buy | $1.42 | 20,000 | $28,400.00 | 320,000 |
Latest Compass Therapeutics Inc. News
CMPX Breaking Stock News: Dive into CMPX Ticker-Specific Updates for Smart Investing
GlobeNewswire
17 days ago
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
Simply Wall St.
17 days ago
Compass Therapeutics And 2 More Compelling Penny Stocks
GlobeNewswire
18 days ago
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
GlobeNewswire
19 days ago
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
Simply Wall St.
a month ago
With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest
Insider Monkey
2 months ago
Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025
GlobeNewswire
2 months ago
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Simply Wall St.
2 months ago
3 Penny Stocks On US Exchanges With Market Caps Under $500M
Compare CMPX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CMPX Compass Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.